Log in
NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$1.79
+0.06 (+3.47 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.73
Now: $1.79
$1.80
50-Day Range N/A
52-Week Range
$1.15
Now: $1.79
$3.51
Volume157,091 shs
Average Volume699,213 shs
Market Capitalization$120.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also developes DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Read More
OncoCyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515
Employees33

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$120.38 million
Next Earnings Date3/24/2021 (Estimated)
OptionableNot Optionable
$1.79
+0.06 (+3.47 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OncoCyte
.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) announced its quarterly earnings results on Thursday, November, 12th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.01.
View OncoCyte's earnings history
.

What price target have analysts set for OCX?

6 analysts have issued 1 year price targets for OncoCyte's shares. Their forecasts range from $2.00 to $6.00. On average, they expect OncoCyte's stock price to reach $3.83 in the next twelve months. This suggests a possible upside of 114.2% from the stock's current price.
View analysts' price targets for OncoCyte
.

Are investors shorting OncoCyte?

OncoCyte saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 2,330,000 shares, a drop of 17.1% from the September 30th total of 2,810,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the short-interest ratio is currently 1.9 days.
View OncoCyte's Short Interest
.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 60, Pay $312.5k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg Ph.D., Chief Scientific Officer
  • Mr. William Annett, Advisor (Age 66, Pay $673.33k)
  • Mr. Albert P. Parker II, COO & Sec.
  • Mr. Tony T. Kalajian CPA, M.B.A., Sr. VP & Chief Accounting Officer
  • Ms. Padma Sundar, Sr. VP of Commercial
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Medical Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 67)
  • Ms. Sara Riordan, Director of Medical Education

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.90%), State Street Corp (1.02%), Phoenix Holdings Ltd. (0.47%), Bank Julius Baer & Co. Ltd Zurich (0.40%), Penbrook Management LLC (0.34%) and GSA Capital Partners LLP (0.30%). Company insiders that own OncoCyte stock include Albert P Parker, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Morgan Stanley.
View insider buying and selling activity for OncoCyte
.

Which major investors are buying OncoCyte stock?

OCX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP, Bank Julius Baer & Co. Ltd Zurich, State Street Corp, Perkins Capital Management Inc., California State Teachers Retirement System, Phoenix Holdings Ltd., and Penbrook Management LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.79.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $120.38 million. OncoCyte employs 33 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.